India, July 1 -- Creative Medical Technology Holdings, Inc. (CELZ), a clinical-stage biotechnology company, issued a mid-year update from its President and CEO, Timothy Warbington.
Creative Medical focuses on developing regenerative medicine therapies derived from adult and perinatal stem cell technologies, and CELZ-201 (Olastrocel) is the company's lead clinical asset in development for chronic lower back pain. The company is currently advancing CELZ-201 toward Phase 3 readiness in chronic lower back pain.
The company's other core programs include Ultrasome Knee Osteoarthritis(OA) program and CELZ-Biodefense Platform.
The near-term milestones for Olastrocel, Ultrasome OA studies and CELZ-Biodefense Toxic Exposure Atlas highlighted by th...